Dr Lance O’Sullivan: Prevention and Precision
Kaitaia doctor, author, health advocate and 2014 New Zealander of the Year Dr Lance O’Sullivan opened Diabetes NZ’s 2019 Find the 100,000 video. He wants to get some clear messages across.
With a passionate commitment to improving health in rural and low-income communities, Dr O’Sullivan says, “I am always 100 percent behind anything that will increase people’s earlier and better management of their own health.
“I want people out there to know that the power is in their hands. I believe, though, we need to make sure two audiences are hearing advocacy work around diabetes awareness: One is the population of people in this country. Two is government.”
He says the biggest barrier to people with type 2 or pre-diabetes being diagnosed is access to primary healthcare. “It’s a big limiting step for people, and particularly Māori and Pacific people.
“The other thing is that people who do get to primary care aren’t always being screened as they should be, and that’s because of a sense of urgency or pressure from the Health Service. Then finally there’s education: people’s understanding around their risk of diabetes and the potential symptoms. Education can’t be just pamphlets, can’t be adverts. That’s not working. We’ve got to do something different.”
Innovative work
Dr O’Sullivan says that better access to primary care is urgent, and that this means reinventing what primary care looks like. He is leading two initiatives that work on just that – iMOKO and MaiHealth. These allow people who live far from doctors, and cannot afford the time or transport to reach them, to access quality healthcare through innovative use of technology.
A recent announcement by Pharmac that they will consider new diabetes drugs has been welcomed in many quarters, but Lance admits it’s not something he can fully celebrate. “It’s putting more ambulances at the bottom of the cliff.” For him, the key is, “How do we get better prevention, and also understanding of selfmanagement of diabetes?” He says, “Let’s have medication as the final step in our arsenal. I want to be talking about how we prevent this tsunami of complications of diabetes-related conditions.”
In Kaitaia, he leads a genetic research program. “We’re looking at genetic variants that predict the likelihood of people having diabetes. That’s going to be phenomenal. Imagine a baby being born, and being able to do a test to say, look, at 40 years of age, if you have these characteristics, you have a 90% chance of having diabetes. And then we could say, you have then a 50% chance of an amputation of a limb within 10 years of the diagnosis.
“These things are incredible in terms of the opportunity to say to people very early, “let’s turn the dial, and prevent you actually ending up with these unnecessary and preventable conditions, through management of your lifestyle, and then optimal medical management if needed.”
Any medical management can be made smarter too. “I’d like to see more pharmacogenetics: being able to offer precise, targeted use of medications.” Research already shows that genetics determine how well people respond to different diabetes medications.
“There’s lots of opportunity around saying, okay, can we check the genotype of people to see whether metformin is actually the best medication for their diabetes and, if not, what is? So I would like to see Pharmac investing in smarter, precision medicine.”